Nuvation Bio Finalizes $250M Convertible Note Offering at 35% Premium
NUVB has more than doubled off its 52-week low of $1.81 on elevated volume (6.9× avg).
Summary
Nuvation Bio finalized a $250 million convertible senior note offering with a 35% premium conversion price, using proceeds to repay debt and for general corporate purposes, enhancing financial stability.
Key Events · Financing and Capital Events · NUVB
-
Finalized Convertible Note Offering
Nuvation Bio finalized an offering of $250 million in 0.75% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $37.5 million.
-
Premium Conversion Price
The initial conversion price is approximately $7.84 per share, representing a 35% premium over the Class A common stock's last reported sale price of $5.81 on June 25, 2026.
-
Use of Proceeds
Net proceeds of approximately $241.2 million (or $277.6 million if the over-allotment option is fully exercised) will be used to repay $50 million in existing secured debt, fund $14.9 million for capped call transactions, and for general corporate purposes.
-
Dilution Mitigation
Capped call transactions were entered into to generally reduce potential dilution to Class A common stock upon conversion and/or offset cash payments, subject to a cap price of $10.4580.
Analysis · NUVB · Life Sciences
Nuvation Bio has finalized its offering of $250 million in 0.75% Convertible Senior Notes due 2032, with an initial conversion price of approximately $7.84 per share. This conversion price represents a significant 35% premium over the Class A common stock's last reported sale price of $5.81 on June 25, 2026. The company plans to use the net proceeds to repay $50 million in existing secured debt and for general corporate purposes, including funding capped call transactions to mitigate potential dilution. This substantial capital raise, secured on favorable terms, strengthens the company's balance sheet and provides additional financial flexibility, following strong Q1 2026 results.
At the time of this filing, NUVB was trading at $5.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $1.81 to $9.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.